Total Payments
$1.3M
2024 Payments
$199,354
Companies
14
Transactions
839
Payment Breakdown by Category
Other$1.1M (84.6%)
Travel$189,808 (14.1%)
Consulting$11,016 (0.8%)
Food & Beverage$6,244 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 277 | 78.6% |
| Travel and Lodging | $189,808 | 452 | 14.1% |
| Honoraria | $71,780 | 21 | 5.3% |
| Consulting Fee | $11,016 | 6 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,200 | 3 | 0.7% |
| Food and Beverage | $6,244 | 80 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $297,769 | 132 | $0 (2024) |
| PFIZER INC. | $226,913 | 168 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $194,729 | 128 | $0 (2022) |
| Janssen Biotech, Inc. | $170,177 | 100 | $0 (2024) |
| ABBVIE INC. | $111,338 | 109 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $106,168 | 52 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $88,454 | 50 | $0 (2017) |
| Horizon Pharma plc | $52,675 | 31 | $0 (2018) |
| Gilead Sciences, Inc. | $50,942 | 34 | $0 (2019) |
| Horizon Therapeutics plc | $19,225 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $199,354 | 117 | Janssen Biotech, Inc. ($80,062) |
| 2023 | $105,466 | 63 | Janssen Biotech, Inc. ($90,099) |
| 2022 | $186,692 | 92 | Takeda Pharmaceuticals U.S.A., Inc. ($92,600) |
| 2021 | $112,209 | 56 | Takeda Pharmaceuticals U.S.A., Inc. ($54,983) |
| 2020 | $40,801 | 25 | PFIZER INC. ($14,345) |
| 2019 | $238,917 | 158 | PFIZER INC. ($110,683) |
| 2018 | $245,691 | 174 | Janssen Scientific Affairs, LLC ($53,702) |
| 2017 | $217,461 | 154 | Takeda Pharmaceuticals America, Inc. ($88,454) |
All Payment Transactions
839 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $745.17 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $305.44 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $223.03 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $65.14 | General |
| Category: Immunology | ||||||
| 12/12/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $157.10 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $662.64 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $302.99 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $208.32 | General |
| Category: Immunology | ||||||
| 12/05/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $126.35 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $100.85 | General |
| Category: Immunology | ||||||
| 12/04/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $1,445.37 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $206.18 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $195.70 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $182.08 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $611.93 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $189.16 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $1,082.94 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $380.60 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $221.95 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $51.90 | General |
| Category: Immunology | ||||||
About Dr. Peter Mcnally, DO
Dr. Peter Mcnally, DO is a Gastroenterology healthcare provider based in Ft Carson, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013987965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Mcnally, DO has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $199,354 received in 2024. These payments were reported across 839 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Ft Carson, CO
- Active Since 01/24/2006
- Last Updated 04/14/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1013987965
Products in Payments
- STELARA (Biological) $292,060
- ENTYVIO (Biological) $199,673
- Entyvio (Biological) $186,550
- XELJANZ (Drug) $130,122
- ZEPOSIA (Drug) $107,491
- TREMFYA (Drug) $72,846
- Humira (Biological) $63,345
- PRIMARY CARE - DISEASE STATE (Drug) $52,675
- VELSIPITY (Drug) $48,539
- Epclusa (Drug) $46,792
- INFLECTRA (Biological) $38,697
- VOQUEZNA (Drug) $13,729
- APRISO (Drug) $6,825
- DUEXIS (Drug) $3,600
- SKYRIZI (Biological) $75.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.